Clinical study on Shensong Yangxin Capsule combined with rivaroxaban in the treatment of middle and high risk at-rial fibrillation patients with deficiency of both qi and yin
Liang Disai
Bao Xinyi
Liu Sihan
Yuan Ding
Abstract：Objective To explore the clinical efficacy of Shensong Yangxin Capsule combined with rivaroxaban in the treatment of middle and high risk atrial fibrillation with deficiency of both qi and yin.Methods From June 2022 to June 2024,100 patients with moderate and high-risk atrial fibrillation of deficiency of both qi and yin were selected and divided in-to treatment group and control group according to random envelope and double-blind method,with 50 cases in each group.The control group was treated with rivaroxaban,while the treatment group was treated with Shensong Yangxin Capsule.The clinical efficacy and incidence of adverse reactions of the two groups were evaluated.The TCM syndrome score,inflammatory factors[Interleukin-6(IL-6),High-sensitivity C-reactive protein(hs-CRP)],Insulin-like growth factor(IGF-1),Thyroid stimu-lating hormone(TSH)and P-selectin(GPM-140)were compared between the two groups before and after treatment.Results The effective rate in the treatment group was significantly higher than that in the control group(x2/P=6.859/＜0.001).After treatment,the scores of TCM syndromes,IL-6,hs-CRP,IGF-1,TSH and GMP-140 in the treatment group were lower than those in the control group(t/P=5.378/＜0.001,9.444/＜0.001,7.155/＜0.001,5.602/＜0.001,7.344/＜0.001,9.029/＜0.001).There was no significant difference in adverse reactions between the treatment group and the control group(P＞0.05).Conclusion Shensong Yangxin Capsule combined with rivaroxaban can effectively control the symptoms of patients with atrial fibrillation of deficiency of both qi and yin,improve TCM syndromes,and reduce the risk of inflammatory factors and stroke.
Keywords：Atrial fibrillationDeficiency of both qi and yinShensong Yangxin CapsuleRivaroxabanInflammatory factor
Publication Date：2025-09-18
Online Publishing Date：2025-10-11(First online date of this platform, not the publication date of the document)
Pages：4( 1036-1039 )